The announcement of positive preliminary data from a clinical trial is typically seen as a positive development for a biotech company like Janux Therapeutics. The lack of dose-limiting toxicities suggests that the drug is safe at the tested doses, which could potentially lead to regulatory approval in the future. This could boost investor confidence in the company and potentially lead to a short-term increase in the stock price.